Literature DB >> 26863360

Von Willebrand Factor--A New Target for TTP Treatment?

Agnès Veyradier1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26863360     DOI： 10.1056/NEJMe1515876

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

1.  Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.

Authors:  Elie Azoulay; Philippe R Bauer; Eric Mariotte; Lene Russell; Paul Knoebl; Ignacio Martin-Loeches; Frédéric Pène; Kathryn Puxty; Pedro Povoa; Andreas Barratt-Due; Jose Garnacho-Montero; Julia Wendon; Laveena Munshi; Dominique Benoit; Michael von Bergwelt-Baildon; Marco Maggiorini; Paul Coppo; Spero Cataland; Agnès Veyradier; Andry Van de Louw
Journal:  Intensive Care Med       Date:  2019-10-07       Impact factor: 17.440

2.  Prognostic risk-stratified score for predicting mortality in hospitalized patients with thrombotic thrombocytopenic purpura: nationally representative data from 2007 to 2012.

Authors:  Ruchika Goel; Karen E King; Clifford M Takemoto; Paul M Ness; Aaron A R Tobian
Journal:  Transfusion       Date:  2016-04-15       Impact factor: 3.157

Review 3.  Platelets and platelet adhesion molecules: novel mechanisms of thrombosis and anti-thrombotic therapies.

Authors:  Xiaohong Ruby Xu; Naadiya Carrim; Miguel Antonio Dias Neves; Thomas McKeown; Tyler W Stratton; Rodrigo Matos Pinto Coelho; Xi Lei; Pingguo Chen; Jianhua Xu; Xiangrong Dai; Benjamin Xiaoyi Li; Heyu Ni
Journal:  Thromb J       Date:  2016-10-04

4.  A dramatic recovery in a patient initially expected to die of TTP & its complications.

Authors:  Jennifer Ogilvie; Jaskeerat Singh
Journal:  J Community Hosp Intern Med Perspect       Date:  2018-06-12

Review 5.  The Long and Winding Road for New Treatments for Acquired Thrombotic Thrombocytopenic Purpura.

Authors:  Roger E G Schutgens
Journal:  Hemasphere       Date:  2019-01-23

6.  Refractory Auto-Immune Thrombotic Thrombocytopenic Pupura Successfully Treated With Caplacizumab.

Authors:  Chloé Mellaza; Nicolas Henry; Pierre-Marie Fayolle; Satar Mortaza; Jean-François Subra; Agnès Veyradier; Paul Coppo; Jean-François Augusto
Journal:  Front Med (Lausanne)       Date:  2020-10-22

7.  Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the Caplacizumab era.

Authors:  Andry Van de Louw; Eric Mariotte; Michael Darmon; Austin Cohrs; Douglas Leslie; Elie Azoulay
Journal:  PLoS One       Date:  2021-08-12       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.